Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ABTX - Agribiotech -- Ignore unavailable to you. Want to Upgrade?

To: M. Carver who wrote (7086)	1/21/1999 11:14:00 PM
From: Osothebear_517	Respond to of 8359

I'll be there and I have every confidence that it will be a celebration. OSO

To: M. Carver who wrote (7086)	1/22/1999 6:40:00 AM
From: Big Dog	Read Replies (2) \| Respond to of 8359

Dear Mark: You stated that: "What I find more puzzling is a feeling out here by some shareholders that ABTX won't follow through with their original timetable." It's not that I (or others) feel that ABTX management is not trying very hard to meet the publicly stated timetable. The issue is "whether the potential acquiror is using the 'self-imposed timetable, shareholder expectations, and financial conditions' to their advantage to negotiate a lower price?" If they are, Dr. Thomas may have a fiduciary duty to us shareholders to back-off of the timetable to get us and the company a better deal. That's all.

To: M. Carver who wrote (7086)	1/22/1999 8:26:00 AM
From: Jack Jackson	Read Replies (1) \| Respond to of 8359

Related Quotes ABTX 0 +0 delayed 20 mins - disclaimer Friday January 22, 7:46 am Eastern Time Company Press Release AgriBioTech Inc. Announces Appointment of Director of Biotechnology Laboratory and Program HENDERSON, Nev.--(BUSINESS WIRE)--Jan. 22, 1999--Kent Schulze, president and chief operating officer of AgriBioTech Inc. (Nasdaq/NM:ABTX - news; ''ABT'') Friday announced that the company has appointed a former Mycogen Corp. scientist to direct and manage ABT's biotechnology laboratory. Dr. Candace G. Poutre joins ABT as director of molecular and cell biology, reporting to Dr. Tom Rice, vice president and director of research. Poutre will be responsible for building and managing ABT's biotechnology laboratory located on the campus of the University of Rhode Island at Kingston. She joins ABT from Mycogen (now a wholly owned subsidiary of The Dow Chemical Co.: DOW) where for the past four years she had been director of molecular biology and biochemistry, and held other important science research and management positions for the past 11+ years with various units of what evolved into Mycogen. ''We are pleased to announce that Dr. Poutre has joined ABT in this important role,'' said Rice. ''I look forward to working with her to take full advantage of the many biotechnology assets and agreements we have completed in the past seven months. Our goal is to build a world-class biotechnology unit that supports our long-term plan to lead the forage and turfgrass seed sector into the next century.'' Poutre is a recognized industry leader in seed and plant biotechnology research and has had two important patents issued in the field, as well as numerous publications. She earned her Ph.D. in molecular genetics from the Department of Genetics and Development at Cornell University, Ithaca, N.Y., in 1986. Among other things, at Mycogen she led a successful discovery program for insect-resistant genes in several crop plants, including corn, cotton, alfalfa, sunflower, soybean, wheat, sorghum and rice. At Mycogen, she was also responsible for adequately resourcing and implementing the transgenic plant product registration strategy. Since June 1998, ABT has announced six important biotechnology alliances and/or agreements that relate directly to the work that Poutre will do at the company: (1) the Noble Foundation to gain for ABT exclusive worldwide rights and access in alfalfa to genes that may improve digestibility; (2) Global Agro Inc. to gain for ABT worldwide rights, exclusive for all turfgrass and key forage grass species, to technology at Global Agro that appears to regulate plant growth and development; (3) a Bt agreement with Mycogen to jointly develop and market insect-resistant alfalfa varieties using Mycogen Bt technology, and to proceed with priority negotiations on insect-resistant turfgrasses; (4) a research license from Garst Seed Co. (part of the global Advanta seed group) for access to ''whiskers'' transformation technology for all forage and turfgrasses and an option, at ABT's discretion, for a commercialization license; (5) The University of Rhode Island to lease space and establish an ABT molecular biology and transformation laboratory; and, (6) purchase of an equity position in Kimeragen Inc. and an exclusive worldwide license to Kimeragen technology involving chimeraplasty for all forage and turfgrass species, subject to two previous nonexclusive licenses. In addition, the company has announced two other product research and development agreements. AgriBioTech is a fully integrated full-service seed company specializing in the forage and turfgrass seed sector, complete with research and development of proprietary seed varieties, seed processing plants, and a national and international distribution and sales network. The company has completed 33 acquisitions since Jan. 1, 1995, and is the largest forage and cool-season turfgrass seed company in the world, with a current level of annualized net sales of approximately $455 million, including the previously announced pending acquisitions of Moore Seed Processors and Production Plus+, which have annualized net sales aggregating approximately $15 million. The statements discussed in this news release include forward-looking statements that involve a number of risks and uncertainties. These include the company's historical lack of profitability, need to manage its growth, intense competition in the seed industry, seasonality of quarterly results, weather conditions, volatile stock price and other risks detailed from time to time in the company's Securities and Exchange Commission reports. -------------------------------------------------------------------------------- Contact: AgriBioTech Inc., Henderson John Francis, 702/566-2440 702/566-2450 (fax) www.agribiotech.com -------------------------------------------------------------------------------- More Quotes and News: Agribiotech Inc (Nasdaq:ABTX - news)